Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

December 19, 2014
Life sciences
GlaxoSmithKline’s shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.
 
For starters, there’s the multibillion-dollar asset swap with Novartis that the companies announced in April. On Thursday, the British pharma’s investors approved the deal–which will send GSK’s oncology assets over to Switzerland and bring most of Novartis’ vaccines business over in return, as well as form a joint venture in consumer health–by an “overwhelming majority,” according to Reuters.
 
As Glaxo said in April, the transaction will up its annual revenue by £1.3 billion. And as Witty reiterated on Thursday, after next year’s slated deal close, the company will return £4 billion to shareholders, Bloomberg reports.
 
And despite rumors that the pharma giant would cut its dividend on its top-line struggles, Witty confirmed his company plans to maintain 2014’s dividend of 80 pence a share next year, remarking that investors shouldn’t be worried.
 
But considering Glaxo’s bleak sales picture as of late, it’s no surprise that some of them found pause for concern. Top product Advair plunged 25% last quarter, fueling a 12% pharmaceutical sales slide. And that’s only set to continue as copycats eat away at the one-time $8-billion-a-year seller; in preparation, the drugmaker this year initiated a $1.6 billion restructuring, which most recently claimed at least 900 sales and R&D jobs focused in Research Triangle Park, NC.
 
By Carly Helfand
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach